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Mendelian-inherited heart disease: a gateway to  
understanding mechanisms in heart disease  
update on work done at the university of stellenbosch
PA BRINK, JC MOOLMAN-SMOOK, VA CORFIELD
Nature is nowhere accustomed more openly to display her secret 
mysteries than in cases where she shows traces of her work-
ings apart from the beaten path; nor is there any better way 
to advance the proper practice of medicine than to give our 
minds to the discovery of the usual law of nature by the careful 
investigation of cases of rarer forms of disease. For it has been 
found in almost all things, that what they contain of useful or of 
applicable nature, is hardly perceived unless we are deprived of 
them, or they become deranged in some way.
William Harvey, 1657
summary
The presence of founder effects in South Africa for many 
single-gene diseases, which include heart diseases such as 
progressive familial heart block types I and II, hypertrophic 
cardiomyopathy and the long QT syndromes, afforded us the 
opportunity to identify causal genes and associated muta-
tions through genetic mapping and positional cloning. From 
finding the genes, the emphasis has shifted to elucidating how 
primary defects cause disease and recognising factors that 
could explain the often pronounced phenotypic variability 
seen in persons carrying the same inherited defect. In some of 
these diseases, sudden unexpected death has been a frequent 
occurrence in young, apparently healthy individuals who had 
not been aware that they had inherited an underlying risk. 
Herein, we review progress in identifying genes, mutations 
and risk factors associated with the diseases mentioned.
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The increasing availability, in the latter parts of the previous 
century, of DNA polymorphisms (markers) with known chro-
mosomal locations allowed researchers to follow the inheritance 
of any chromosomal segment in families.1 With gene location 
searches no longer restricted to blood groups, the HLA system 
and serum protein polymorphisms, the position of any disease 
phenotype that segregated in a Mendelian fashion could be 
addressed. An early success with the new resources was with 
Huntington’s chorea. This autosomal dominantly (AD) inherited 
condition, which, besides the onset of the movement disorder, is 
also associated with dementia, was mapped to chromosome 4.2 
Knowledge of the approximate chromosomal position immedi-
ately provided the means to identify at-risk and not-at-risk indi-
viduals in families, using linked DNA markers. At the same time, 
it paved the way to identifying the causal gene by systematically 
exploring genes, both known and at the time still unknown, at the 
identified chromosomal segment for the disease-causing muta-
tion.1 Appropriately named ‘positional cloning’, this approach 
became a paradigm for discovering the cause of many of the 
more than 6 000 known Mendelian-inherited characteristics, 
most with no known pathophysiological mechanisms.1
In this milieu, confronted with an AD inherited cardiac 
bundle branch disorder, progressive familial heart block type 
I (PFHBI),3 and with no idea how to approach the cause from 
a pathophysiological rationale, the logical step was positional 
cloning. In this way, the condition was mapped to chromosome 
19q134 and a novel causal gene, TRPM4, a member of the tran-
sient receptor potential melastatin (TRPM) family of ion channel 
genes, was recently identified (manuscript submitted).
Developing a focus on inherited heart disease and using 
molecular genetics to identify causal genes and associated muta-
tions, we turned our attention to hypertrophic cardiomyopathy 
(HCM) and the long QT syndrome (LQTS), where either single 
individuals or families with more than one affected member 
were available. It was also apparent that, as these disorders are 
more commonly reported than PFHBI, there were better oppor-
tunities for international collaboration in this fast-evolving field. 
Families were expanded by cascade screening and, when neces-
sary, ancestral ties identified by genealogical studies. 
HCM shows an AD pattern of inheritance in a major-
ity of cases and is characterised primarily by thickening of the 
ventricular wall in the absence of other hypertrophy-predispos-
ing conditions.5 LQTS is recognised by episodes of syncope and 
a prolonged QT interval and can either be inherited in an AD 
manner (Romano-Ward syndrome) or autosomal recessive (AR) 
manner where it is associated with deafness (Jervell Lange-
Nielsen syndrome).6 Both HCM and LQTS, together with a 
number of other diseases, many of them inherited in a Mendelian 
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fashion, are important causes of sudden unexpected death (SUD) 
in the young, apparently well person.7 In the case of both HCM8 
and LQTS,9,10 several hundred mutations, each in a number of 
different genes, cause the respective phenotypes. HCM-causing 
mutations occur in 14 causal genes, with 12 of these encoding of 
the cardiac sarcomere, the contractile apparatus of the heart (Fig. 
1).5,8,11 In the case of LQTS, 12 genes have been identified, which 
encode proteins that form ion channel sub-units or proteins that 
affect ion channel functioning.6,10 
In HCM, the causative genes most commonly involved are 
those encoding the cardiac β-myosin heavy chain (MYH7; 
thick filament), cardiac troponin T (TNNT2; thin filament) and 
cardiac myosin-binding protein C (MYBPC3; thick filament)5,8,11 
(Fig. 1); disease-causing mutations have been detected in these 
three genes in South African families with AD patterns of 
inheritance.12-14 Parallel attempts to identify South African fami-
lies segregating dilated cardiomyopathy (DCM) have not been 
successful to date (unpublished observation). In general, DCM 
does not behave as a single gene disease, but globally where 
families segregating DCM in a Mendelian inheritance pattern 
have been identified, the molecular cause has often been found 
to be related to the cytoskeleton of heart cells or to molecules 
that play a role in stabilisation of the nuclear membrane, 
cell–cell contact or connections in between (Fig. 1).5 These 
findings may yet hold importance for progressive familial heart 
block type II (PFHBII), an atrioventricular (AV) nodal disorder, 
which was described concomitantly with PFHBI3 and which has 
been mapped to chromosome 1q32.2-32.3 by the Stellenbosch 
group.15 A follow-up study found that this condition is also often 
associated with DCM.16 
The phenotypic combination of AV nodal disease and DCM 
has often been associated with defects of the cytoskeleton. 
Therefore, once the disease had been mapped to chromosome 
1,15 a compelling candidate gene in the search area was the 
lamin A/C encoding gene (LMNA), which is a cause of Emery-
Dreifuss syndrome, a form of muscular dystrophy associated 
with DCM and conduction defects, as well as a similar isolated 
heart disease.5 However, further high-resolution mapping placed 
LMNA outside the PFHBII-containing interval,15 and the search 
for the causative gene continues.
Worldwide, the genes most commonly encountered as the 
cause of LQTS are KNQ1 and KCNH2, which both encode 
potassium channels, and SCN5A, a sodium channel-encoding 
gene. Depending on the gene involved, which is to some extent 
reflected in the phenotype,17 the disease is sub-classified as 
LQT1-LQT12, for example KCNQ1:LQT1, KCNH2:LQT2. 
Mutations have been detected in South Africa in both KCNQ1 and 
KCNH2, as well as in KCNE1 (Durrheim, unpublished results). 
Fig. 1. Cellular localisation and interactions of proteins involved in hCM and dCM. schematic representation of a 
section through part of a cardiac myocyte, illustrating the position and interactions of many of the various proteins 
that have been implicated in hCM and/or dCM (from reference 5).
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The motivation for mapping and identifying disease-causing 
genes and associated mutations is that, not only will one be able 
to predict the recurrence of risk in families, but one would also 
be able to study and understand the diseases better. However, 
although identifying mutation carriers in affected families is a 
simple technicality, prediction has proved less tractable. Even 
with closely linked markers or with the mutation itself in hand, 
it soon became clear to us that, in all of the cardiac diseases 
studied, not all mutation carriers (MCs) would manifest disease 
by clinical criteria. In HCM, as much as 30% will have no clini-
cal evidence of disease, yet will have increased risk of untoward 
events, for example SUD.5 Therefore, the disease allele (genotype) 
imparts the major risk, but is not the sole determinant of risk. 
A further surprise was the extent to which some HCM and 
LQTS disease alleles displayed founder effects, as seen in 
PFHBI (Table 1). One of the reasons for a founder effect is a 
population bottleneck where a reduction in population numbers, 
e.g. caused by population decimation or by a migratory event, 
leads to reduction in genetic diversity and to different allele 
frequencies. The new expanding population will then have a 
genetic mix different to that of the parent population(s). Such 
migrations did occur with the Dutch occupation of the Cape of 
Good Hope in 1652 and also with the importation of slaves from 
Madagascar, east Africa and the Far East. Many founder effects 
have been described, especially in the descendants of the Dutch 
settlement (Dutch, French, German), the Afrikaner population.18
In almost all cases, a founding couple who lived prior to 
1730 can be identified, e.g. in PFHBI (E7KTRPM4b), a couple 
in the eastern Cape (13 families; 84 MCs identified),4 and in 
LQT1 (A341VKCNQ1), a couple in the southern Cape (22 families; 
172 MCs) (Fig. 2).19 The associated haplotype (chromosomal 
marker background) supports the notion that these two muta-
Fig. 2. Example of a founder effect reproduced from reference 19. lines of descent of the A341vKCNQ1 (lQt1) mutation 
from a common founder couple, P, are shown. the haplotype that segregates with the mutation is consistent with a 
common origin of the mutation. genealogical information for pedigree 170 and 180, a single individual, could not be 
found. haplotypes were constructed from the results of the combination of alleles inherited at d11s4046, d11s1318, 
A341v, d11s4088, d11s4146, d11s4181, d11s1871, d11s1760 and d11s1323 in the order telomere to centromere. 
Common haplotypes are bordered. index cases are shown as diamonds to preserve anonymity. Circles denote females 
and squares males in the line of descent. Ped indicates pedigree. year of birth is shown below individuals. the letters P, 
Q, and t refer to couples in the first two generations from which the mutation descended. some individuals have more 
than one line of descent from the founding couple. For simplicity, only the line deemed most likely has been shown.
TABLE 1. FOUNDER MUTATIONS DETECTED IN  
STELLENBOSCH GROUP’S INVESTIGATIONS
Disease Gene Mutation
Number of 
families
Number of  
mutation carriers
PFHBI TRPM4 E7K 13 84
HCM TNNT2 R92W 12 25
HCM MYH7 A797T 14 80
HCM MYH7 R403W 3 31
LQTS KCNQ1 A341V 23 172
Diseases, genes and mutations for which strong founder effects have 
been identified. PFBHI = progessive familial heart block type I; HCM 
= hypertrphic cardiomyopathy; LQTS = long QT syndrome.
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tions are identical by descent (same mutation; same mutation 
event) for the respective diseases. In HCM, three mutations are 
commonly found in the HCM population, R92WTNNT2 (12 fami-
lies; 52 MCs); A797TMYH7 (14 families; 80 MCs); R403WMYH7 (3 
families; 31 MCs), again with molecular genetic evidence that 
they are founder effects.13 The A797TMYH7 mutation is interesting 
as it represents a mix of families of mixed ancestral (MA) and 
Afrikaner descent, while R92WTNNT2 and R403WMYH7 are only 
found in families of MA. Genealogical studies have not been 
done and may be difficult, as the history of the founding of 
South African sub-population groups may present challenges in 
ancestry tracing.
Having many individuals sharing the same disease-associated 
mutation offers the opportunity to observe phenotypic differ-
ences influenced by environmental or genetic factors other than 
the primary mutation. Furthermore, as implied at the outset of 
our studies, knowing the causal gene and its associated mutations 
creates opportunities to design laboratory-based experiments to 
facilitate further understanding of specific diseases. 
In trying to tease out factors influencing disease expression, 
we generally follow a strategy of comparing selected clini-
cal measurements of MCs with non-mutation-carrier relatives 
(NMCs), as genetically or environmentally driven differences 
between families in demographic and other characteristics which 
influence cardiac function and structure may exist. Where there 
are large enough numbers of subjects, as with the three HCM-
causing mutations, we also compare MCs with different muta-
tions with each other.
severity of the lQt1 A341vKCNQ1 mutation
The degree of clinical severity associated with A341VKCNQ1 was 
quite surprising, with 79% of MCs becoming symptomatic, 
versus 30% for all LQTS from an international database. Persons 
with the A341V mutation became symptomatic at an earlier age 
and experienced more LQTS-related death (Fig. 3).19 A partial 
explanation is that in patch-clamp experiments,19 A341V has a 
moderate dominant-negative effect and not a pure loss of func-
tion as previously suggested. Arrhythmic risk was even higher 
when the A341V carriers were compared with those harbour-
ing KCNQ1 mutations with a strong dominant-negative effect, 
suggesting an additional effect that we are not currently consid-
ering.19
influence of Qtc and autonomic nervous 
system on disease severity in A341vKCNQ1
Virtually every A341VKCNQ1 MC with a QTc > 500 ms has 
episodes consistent with this being recognised as a major risk 
predictor.20 However, in those with a QTc < 500 ms, a number of 
adults have never experienced any attacks, and this was associ-
ated with lower resting heart rates in our study.19,21 Intuitively, 
one assumes the low heart rate to be due to increased vagus 
tonus. However, ‘relatively low’ BRS is significantly more 
present in asymptomatic MCs,21 contrary to the experience with 
post-myocardial infarction (MI) subjects where lower degrees of 
BRS (poor vagus responses) have been associated with a higher 
frequency of sudden death.22 This combination of lower heart 
rates and lower BRS signifies a blunted autonomic response. This 
response would, in theory, avert rapid heart rate changes which 
are potentially dangerous in LQT1 individuals with reduced IKs 
repolarising channel and inappropriate shortening of the QT 
interval.21 We have identified a physiological risk modifier with 
opposing effects in different arrhythmogenic substrates.21
Pregnancy risk in lQt1
When comparing pregnancies in South African A341VKCNQ1 MCs 
and NMCs and in MCs on and off β-blocker therapy in nine-
month blocks before, during and after pregnancy, LQT1-affected 
pregnant women were at low risk for cardiac events and had no 
events when β-blockers were used.23 The perception of increased 
risk in the post-partum period evidenced in an earlier systematic 
study24 in non-genotyped LQTS could possibly be explained by 
the unrecognised presence of LQT2 individuals.25 By contrast, 
in our study, there was no excess risk of miscarriage and no 
segregation distortion, implying no selection against LQT1 MCs 
in utero. An excess of Caesarean sections in MCs was noticed. 
We surmised that the known tendency to bradycardia of LQT1 
MCs possibly leads to misdiagnosis of foetal distress in a number 
of cases.23 
genetic modifiers of left ventricular  
hypertrophy
In contrast to studies of the heart in hypertension, studies of 
HCM generally do not account for variables such as age, gender, 
body surface area, heart rate and systolic and diastolic blood 
pressure that may vary in conjunction with ventricle dimen-
sions. In our studies, these variables were incorporated into a 
mixed-effect model, a model that also takes into account family 
relatedness, environment and polygenes. The hypothesis that 
variation at the angiotensin-converting enzyme 2 gene (ACE2) 
may modify the extent of hypertrophy was then tested in a group 
consisting of MCs and their NMC relatives. ACE2 was found to 
be independently associated with the extent of left ventricular 
hypertrophy in HCM.26
Fig. 3. Kaplan-Meier curves of event-free survival in the 
lQt1 database (from Priori, et al.20) population and in the 
sA-A341vKCNQ1 population (reproduced from reference 19). 
the numbers under the curves represent subjects at risk. 
A subsequent study showed a similar survival curve for 
subjects with A341vKCNQ1 from other population groups (same mutation, different mutational event).54 the survival 
curve for all combined A341vKCNQ1 (sA and other ethnic 
groups combined) showed poorer event-free survival 
than a combination of other lQt1 individuals.54
CARDIOVASCuLAR JOuRNAL OF AFRICA • Vol 20, No 1, January/February 2009AFRICA 61
disease progress in hCM – a longitudinal 
study
The conventional view is that HCM features most often develop 
from puberty to early adulthood and then stabilise.27,28 Longitudinal 
studies, however, of the progression of the disease in genotypi-
cally defined patients are sparse,29 in contrast to cross-sectional 
studies such as we and others have reported.30,31 Taking advantage 
of our database of genotyped HCM individuals, many of whom 
had been identified in the 1990s in a previous study, a follow-up 
investigation was undertaken for carriers of the R92WTNNT2 and 
A797TMYH7 mutations. In subjects with apparently mild disease, 
there was a positive correlation between age and interventricular 
septal thickness for both mutations, with more than a third of 
all MCs developing clinically recognised hypertrophy only after 
the age of 35 years.32 Furthermore, statistical modelling detected 
a complicated interplay between unidentified, possibly gender-
associated factors and the causal mutation in cardiac function 
and survival. The period preceding the development of hypertro-
phy also coincided with the years in which most SUDs occurred, 
particularly in male R92WTNNT2 carriers.
32
ventricular function in carriers of hCM- 
causing mutations with no hypertrophy 
Although animal models and in vitro studies suggest distinct 
effects for different mutations,33-36 genotype:phenotype correla-
tion studies in human HCM have generated inconsistent data.37 
Human studies have typically included only individuals with 
fully developed disease, or combined such individuals with 
their sub-clinically affected MC relatives.38 Such studies may 
be confounded by differences in penetrance between mutations 
set against different genetic and environmental backgrounds.39 
Furthermore, interpretation of the consequences of mutations 
on systolic and diastolic function may be confounded by the 
degree of underlying hypertrophy-associated cardiac fibrosis 
and disarray.40 
Cardiac structural and functional parameters were compared 
between pre-hypertrophic South African MCs and NMC family 
members, with adjustment for appropriate covariates. The three 
founder mutations were associated with distinct functional 
effects, whereas the R92WTNNT2 correlated with a relative increase 
in systolic functional parameters, the A797TMYH7 correlated with a 
reduced diastolic function, and the R403WMYH7 with both reduced 
systolic and diastolic function.41 The observed early effects 
of the R92WTNNT2 mutation mechanistically fit with prolonged 
force-transients precipitated by increased Ca2+ sensitivity of the 
thin filament, and that of the MYH7 mutations with local ATP 
depletion.
Functional anatomy of myosin-binding protein 
C (MyBPC)
Myosin-binding protein C (MyBPC) was initially reported in 
197342 but attracted little interest until it was associated with 
a human disease, namely HCM.43 MyBPC is a thick filament-
associated protein localised to the C zones of striated muscle 
sarcomeres (reviewed in Flashman et al.44). A cardiac isoform, a 
fast-twitch and a slow-twitch skeletal muscle form exist. MyBPC 
contributes to thick filament structure via interactions with the 
light meromyosin section of the myosin rod and with titin, while 
also playing a role in the regulation of contraction attributed to 
a binding domain for the subfragment-2 portion of myosin.45 
We performed yeast 2-hybrid experiments to identify ligands of 
specific MyBPC domains that were implicated in HCM patho-
physiology. Important ligands detected were certain domains 
of MyBPC, indicating that MyBPC binds to itself. Based on 
previous biochemical and structural information and our data, 
we proposed a model where three cMyBPC molecules trimerise 
to form a collar around the thick filament (Fig. 4).45 A follow-up 
study clarified differences between cardiac, fast-twitch and slow-
twitch muscle.46
sudden death
In the developed world, the major mode of death is sudden and 
unexpected, albeit even if there was pre-existing heart disease, 
such as a previous myocardial infarction, or the demise of elderly 
individuals.47 In the young below age 35 years, diseases other 
than myocardial infarction should be considered in the event of 
SUD.7,48 In this age group, the incidence of SUD (1:200 000) 
is low in absolute terms and actually falls in the same order of 
magnitude as death due to childhood cancer. A concern is that 
warning signs may be missed or misinterpreted.49,50
In our experience with LQTS in the early 1990s, in persons 
later diagnosed as LQTS affected, but who had a history of tran-
sient loss of consciousness (TLOC), 40% was mis-diagnosed as 
epilepsy and 31% was not diagnosed at all.51 In fact, we surmise 
that TLOC may even be more often misinterpreted in other 
population groups, as perhaps reflected in the racial composi-
tion of index cases in our LQTS, and to an extent also HCM, 
patient databases. To date, not a single black index case appears 
in the LQTS group (total 41), while persons of MA are under-
represented (9.8%) when compared to national demographics for 
Fig. 4. Proposed arrangement of cMyBPC around thick-
filament backbone (from reference 45). Based on previ-
ous data and our own results, we proposed that three 
cMyBPC molecules trimerise to form a collar around the 
thick filament. 
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South Africa, and white subjects constitute 87.8% of the total,52 
with other minorities making up the difference. Apart from our 
own, there have been no other reports of LQTS from Africa. 
In our HCM database, we see a similar under-representation 
for black subjects – 5.1% out of a total of 176 index cases, while 
MA and white subjects are more equally distributed at 51.1% 
and 42%, and inconsistent with national demographics (total 
48.6 million; black 79.2%, MA 9.0%, white 9.2%, Indian/Asian 
2.6%).53 Genetic bias is an unlikely explanation for the demo-
graphics in our databases not following national demographics; 
a more likely explanation relates to missed opportunities to 
diagnose, missed diagnoses and misdiagnoses, and in the case of 
HCM, the real population drainage of our referral centre in the 
Western Cape.52 
Conclusion
Over the years, the notion has been validated that working on 
relatively scarce Mendelian-inherited cardiac diseases prevalent 
in South Africa presented an opportunity to make significant 
contributions in the scientific world, while benefitting many 
individuals and families living with the disease consequences. 
Furthermore, the powerful resource represented by the many 
South African families harbouring founder heart disease-causing 
mutations, and the willing co-operation of many individuals to 
engage in research studies has allowed us unique opportunities to 
gain further insights into these insidious conditions.
We have addressed the challenge that both medical profes-
sionals and the lay public are generally unaware of potential 
unidentified risks of SUD in the young, apparently well indi-
vidual, and have played an important role in establishing PACE 
(Prevent Arrhythmic Cardiac Events); http://www.paceafrica.
org.za/, an organisation that endeavours to increase awareness 
and support where necessary.
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